Figure 5From: The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer The ratio of I 131 -PSCA-mAb in tumor to intramuscular I 131 -PSCA-mAb (T/NT) in the tumor-bearing nude mice at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of I 131 -PSCA-mAb. Back to article page